Synergistic Anticancer Therapy by Ovalbumin Encapsulation-Enabled Tandem Reactive Oxygen Species Generation

Angew Chem Int Ed Engl. 2020 Nov 2;59(45):20008-20016. doi: 10.1002/anie.202006649. Epub 2020 Sep 15.

Abstract

The anticancer efficacy of photodynamic therapy (PDT) is limited due to the hypoxic features of solid tumors. We report synergistic PDT/chemotherapy with integrated tandem Fenton reactions mediated by ovalbumin encapsulation for improved in vivo anticancer therapy via an enhanced reactive oxygen species (ROS) generation mechanism. O2.- produced by the PDT is converted to H2 O2 by superoxide dismutase, followed by the transformation of H2 O2 to the highly toxic . OH via Fenton reactions by Fe2+ originating from the dissolution of co-loaded Fe3 O4 nanoparticles. The PDT process further facilitates the endosomal/lysosomal escape of the active agents and enhances their intracellular delivery to the nucleus-even for drug-resistant cells. Cisplatin generates O2.- in the presence of nicotinamide adenine dinucleotide phosphate oxidase and thereby improves the treatment efficiency by serving as an additional O2.- source for production of . OH radicals. Improved anticancer efficiency is achieved under both hypoxic and normoxic conditions.

Keywords: Fenton reactions; cisplatin; hypoxic; photodynamic therapy; synergistic.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology*
  • Drug Synergism
  • Endocytosis
  • Humans
  • MCF-7 Cells
  • Mice
  • Ovalbumin / chemistry*
  • Photosensitizing Agents / chemistry
  • Photosensitizing Agents / pharmacology*
  • Reactive Oxygen Species / metabolism*

Substances

  • Antineoplastic Agents
  • Photosensitizing Agents
  • Reactive Oxygen Species
  • Ovalbumin